Myelodysplastic Syndromes

Enrollment begins in phase II clinical trial with DN-101 for MDS

Published in Blood Weekly, February 13th, 2003

Novacea, Inc., a privately-held biopharmaceutical company, announced that patient enrollment has begun in a phase II trial of its lead product, DN-101, for the potential treatment of patients with a blood disorder called myelodysplastic syndromes (MDS), a condition for which there is no approved therapy.

The study will evaluate the effect of high dose pulse administration (HDPA) DN-101 (calcitriol) on the anemia and red blood cell transfusion requirements for patients with MDS. Results of previous preclinical and clinical studies have suggested that calcitriol may be useful in treating MDS. Up to 46 patients with low-risk MDS who are red blood cell...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-02-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry